RxDoctor Payments Data

Erica Bertschler, NP

Nurse Practitioner · Brandon, MSNPI 1588752810

Payments from drug & device makers

$1,794in general payments, 2019–2025

Across 79 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$297
  • AbbVie$218
  • GSK$197
  • Abbott$180
  • Inspire Medical Systems, Inc.$164
  • Astellas Pharma US Inc$140
  • plus $599 from 10 others

What the payments were for

  • Food & beverage$1,794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,794 in reported general payments places this provider in the 80th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$67,380
Medicare patients
197
Services billed
2,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$71,905
JardianceEmpagliflozin35$40,415
EliquisApixaban27$19,698
MounjaroTirzepatide12$12,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,081
XareltoRivaroxaban11$8,511
MyrbetriqMirabegron12$8,027
FarxigaDapagliflozin Propanediol12$7,862
Novolog FlexpenInsulin Aspart11$1,582
SynthroidLevothyroxine Sodium18$1,340
Atorvastatin Calcium148$1,097
Potassium Chloride60$1,030
Albuterol Sulfate HfaAlbuterol Sulfate47$1,028
Diclofenac Sodium89$1,011
Rosuvastatin Calcium56$841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$112$71,90552 claims
Boehringer IngelheimJardiance$118$40,41535 claims
PfizerEliquis$26$19,69827 claims
Lilly USA, LLCMounjaro$132$12,32912 claims
GSKTrelegy Ellipta$197$11,08117 claims
Johnson & JohnsonXarelto$17$8,51111 claims
Astellas Pharma US IncMyrbetriq$140$8,02712 claims
AstraZenecaFarxiga$297$7,86212 claims
AbbVieSynthroid$218$1,34018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Brandon

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →